H
eparin is the anticoagulant of choice when a rapid anticoagulant effect is required because its onset of action is immediate when administered by intravenous injection. Heparin is administered in low doses when used for primary prophylaxis and high doses when used therapeutically to prevent recurrent thrombosis. Its use is almost always limited to an in-hospital setting because it must be administered parenterally. When heparin is given in therapeutic doses, its anticoagulant effect must be monitored and the dosage must be adjusted frequently. When long-term anticoagulant therapy is indicated, in-hospital heparin administration is usually followed by treatment with oral anticoagulants. A period of overlap of approximately four days should be used, during which time both anticoagulants are given in combination. Long-term out-of-hospital heparin treatment is used when anticoagulant therapy is indicated in pregnancy and in the rare patient who has development of recurrent venous thromboembolism while being treated with appropriate doses of oral anticoagulants.
Heparin is effective and indicated for the prevention of venous thromboembolism (level I) (see "Prevention of Venous Thromboembolism" by Clagett et al in this issue), for the treatment of venous thromboembolism (level I) for the early treatment of patients with unstable angina (level I) and acute myocardial infarction (level I) in patients who have cardiac surgery under cardiac bypass (level I) (new chapter), who have vascular surgery (level 111), and in selected patients with disseminated intravascular thrombosis (level III).
In this chapter, the mechanism of action of heparin, its pharmacokinetics, anticoagulant effects, and laboratory monitoring will be reviewed. The clinical use of heparin will be summarized briefly since this is discussed in detail in other chapters. In addition, the potential of a new class of heparins, the low molecular weight heparins (LMWHs) will be discussed and their biophysical, pharmacokinetics, antithrombotic, and hemorrhagic properties will be compared with standard heparin.
STRUCTURE A N D MECHANISM OF ACTION OF HEPARIN
Heparin is a glycosaminoglycan (GAG) composed of chains of alternating residues of D-glucosamine and a uronic acid.' Its major anticoagulant effect is accounted for by a unique pentasaccharide with a high affinity binding sequence to antithrombin 111 (ATIII).2-1L The unique sequence is present in only one third of heparin m01ecules.l~~" The anticoagulant effect of heparin is mediated largely through its interaction with ATIII;I4-l7 this produces a conformational change in ATIIIIH-m and so markedly accelerates its ability to inactivate the coagulation enzymes thrombin (factor IIa), factor Xa, and factor IXa.Wf these three enzymes, thrombin is the most sensitive to inhibition by heparin/ATIII .3. [21] [22] [23] [24] [25] Heparin catalyzes the inactivation of thrombin by ATIII by acting as a template to which both the enzyme and inhibitor bind to form a ternary com-coagulant activity; (2) the anticoagulant profile of heparin is influenced by the chain length of the molecules; and (3) the clearance of heparin is influenced by its molecular size, with the higher molecular weight species being cleared from the circulation more rapidly than the lower molecular weight species. This differential clearance phenomenon results in an accumulation in vivo of the lower molecular weight species that have a reduced ratio of antithrombin to anti-factor Xa activity. This effect is responsible for the differences observed when the relationship between the heparin level and the activated partial thromboplastin time (APTT) is assessed in vivo and in vitro, since the lower molecular weight species that are retained in vivo are measured in the anti-factor Xa heparin assay but have minimal effects on the APTT.
ADMINISTRATION, PHARMACOKINETICS, A N D PHARMACODYNAMICS
Heparin is not absorbed after oral administration and, therefore, must be given by injection. The two preferred routes of administration are intravenous and subcutaneous. Intramuscular injection can produce large hematomas caused by accidental puncture of an intramuscular vein and, therefore, should be avoided. There is evidence that heparin administered by intermittent injection is associated with more bleeding than when it is administered by the continuous intravenous route;3y the latter method is, therefore, preferred if heparin is administered intravenously. The efficacy and safety of heparin administered by either the continuous intravenous method or by the subcutaneous route are comparable provided that the dosages used are a d e q~a t e .~~,~~ If, however, the subcutaneous route is selected, the initial dose must be sufficiently high to counteract the reduced bioavailability that occurs when heparin is administered by the subcutaneous route.41 If an immediate anticoagulant effect is required and heparin is administered by subcutaneous injection, the initial dose should be accompanied by an intravenous bolus injection be- cause an anticoagulant effect from subcutaneous heparin is delayed for 1 to 2 h.
Following its injection and passage into the bloodstream, heparin binds to a number of plasma proteins, including histidine-rich glycoprotein (HRGP),42-44 platelet factor IV (PFIV),42.4s v i t r~n e c t i n ,~~ fibronectin,4i and von Willebrand factor (VWF).4X The binding of heparin to these proteins contributes to its reduced plasma recovery (bioavailability) at low concentrations, to the variability of the anticoagulant response to fixed doses of heparin in patients with thromboembolic disorders,4g and to the laboratory phenomenon of heparin r e s i~t a n c e .~ Binding of heparin to VWF results in the inhibition of VWF-dependent platelet f i~n c t i o n .~~ Heparin also binds to endothelial cells and macrophages,s1 a property that contributes to its complicated pharmacokinetics. Heparin is cleared through a combination of a rapid saturable and a much slower firstorder mechanism of clearance.s2-" The saturable phase of heparin clearance is thought to be due to heparin binding to receptors on endothelial cellsss~s6 and macro phage^^^ where it is internalized, depolymerized, and metabolized into smaller and less sulfated forms.",s9 Clearance through the slower nonsaturable mechanism is largely renal. At therapeutic doses a considerable proportion of the administered heparin is cleared through the rapid saturable, dose-dependent mechanism of clearance. Because of these kinetics, the anticoagulant response to heparin at therapeutic doses is not linear but increases disproportionately both in its intensity and duration with increasing dose. Thus, the apparent biologic half-life of heparin increases from approximately 30 min with an intravenous bolus of 25 Ukg, to 60 min with an intravenous bolus of 100 Ulkg, to 150 min with a bolus of 400 U/kg.s2-"
The plasma recovery of heparin is reduceda when the drug is administered by subcutaneous injection in low doses (eg, 5,000 U112 h) or moderate doses of 12,500 U/12 h6I or 15,000 U/12 h.41 However, at high therapeutic doses of heparin (>35,000 Ul24 h), the plasma recovery is almost c~m p l e t e .~
The poor bioavailability of heparin when administered by subcutaneous injection occurs because as heparin enters the intravascular space slowly from subcutaneous depots, it binds to saturable sites on endothelial cells and macrophages where it is internalized and metabolized. Circulating plasma levels are achieved only after these cell surface receptors are saturated, either by a large loading dose or by the cumulative effects of a number of moderately high doses. The difference between the bioavailability of heparin when administered by subcutaneous or intravenous injection was demonstrated strikingly in a study of patients with venous thrombois.^' The patients were randomized to receive either 15,000 U of heparin112 h by subcutaneous injection or 30,000 U of heparin by continuoris intravenoris infusion; both regimens were preceded by an intravenous bolr~s dose of 5,000 U . Therapeutic heparin levels and APTT ratios were achieved at 24 h in only 37 percent of patients who were randomized to receive siibcr~taneous heparin, while therapeutic heparin levels and APTT ratios were achieved at 24 h in 71 percent given an identical dose of heparin by continrious intravenoris infusion.
T h e anticoagulant effects of heparin are risrially monitored by the APTT, a test that is sensitive to the inhibitory effects of heparin on thrombin, factor Xa, and factor IXa. When heparin is admirlistered in fixed doses, the anticoagulant response to heparin varies among sick patients, including those with acrite venous t h r o m b o e m b o l i s m h 2 a n d with myocardial ischemia.",63-M This variability is carised by differences between patients in their plasma concentrations of heparin-neutralizing plasma proteins and in their rates of heparin clearance. There is evidence from subgrorip analysis of cohort studies (level 111) that a relationship exists between the clinical effectiveness of heparin and its effect ex oiuo on the APTT for the following conditions: prevention of recrirren t thrombosis in patients with proximal vein t h r o m b o s i~; " .~ prevention of mural thrombosis in patients with acute myocardial infarction;" prevention of recurrent ischemia in patients following streptokinase therapy for acute myocardial infarction67.M and in the prevention ofcoronary artery reocclusion after thrombolytic therapy with tissue plasminogen activatoP5 (Table 1 ). For this reason, the dose of heparin administered to patients shor~ld b e monitored by laboratory testing and adjristed to achieve a therapeutic level; this anticoagulant effect is referred to as the "therapeutic range." T h e recommended therapt.ritic range for the APTT for the treatment of venoris thrombosis is biised on a stridy performed in rabbits"' that demonstrated that thrombus extension was by a heparin dose that prolonged the APTT ratio to 1.5 to 2.5, corresponding to a heparin level by protiimine titration of thrombin time of0.2 to 0.4 Ulml.
Unfortrinately, the different commercial APTT reagents vary in their responsiveness to h e p a r i r~. " ,~ For many APTT reagents, a therapeiitic effect is achieved by an APTT ratio of 1.5 to 2.5 (me;isr~red by dividing the observed APTT by the mean of the laboratory control APTT). With very sensitive APTT re;igents, the therapeutic range is higher than a ratio of 1 .S to 2.5. while for insensitive reagents the theraperitic range is lower. T h e difference in responsiveness of various APTT test systems to the anticoagrilant efftacts of heparin has been assessed by the College of American Pathologists and the UK External Qrinlity Assessment siirveys and is shown in Figure 2 . Twhnical variables that affect the APTT response to heparin are the type of clot detection system, the cucontact activiitor, and the phospholipid composition of the reagent." Important variations in the responsiveness to heparin between dfierent batches of the same brand of APTT reagent have also been reported."' T h e response of the APTT ratio to heparin is reduced by the elevated levels of prtmcoagulants that cxcrir in a number of clinical states, including pregnancy, malignancy, acrite thrombosis, and major surgery. Some APTT systems are accelerated by the prt~oagulants more than others giving different APTT ratios with the same concentrations of heparin. An ideal APTT system shorild give a linear relationship over :l clinically relevant anticoagr~lant range. Efforts are being made to develop standards for the APTT system, but an international standard is not yet available. Until there is a reliable system of APTT standardization for heparin monitoring, therapeutic ranges shorild be established in e;ich local laboratory. An approximation of the theriiperitic range of 0.2 to 0.4 U/ml of heparin (by protnmine titration) can be made by testing the APTT reagent in ;I plasma system that has been calibrated by addition of a range of clinically relevant concentrations of heparin. A cumbersome but nlore a c c~~r ; i t e method is to compare APTT ratios with measr~red heparin 1t.vt.l~ (by protamine titration) in plasma samples obtained from patients treated with heparin.
Although there is good evidence that APTT ratios above the lower limit of the theraperitic range are associated with protection against throml)osis,"."' "'-'" maintaining the APTT in the therapelltic range does not guarantee protection from bleeding complications. The risk of bleeding complications is increased with increasing heparin dose".'2 (which in trirn is related to the anticoagrilant response), but other clinical iulml factors, partictdarly recent surgery, trauma, invasive procedures, an occult local lesion (such as an ulcer, renal calculus, or malignant neoplasm), or a generalized hemostatic abnormality are at least as important predictors of bleeding during heparin treatments7"
A less intense anticoagulant effect is required to prevent venous thrombosis with heparin than to treat established thrombosis. Low-dose heparin, 5,000 U subcutaneously two or three times daily, is highly effective in preventing venous thrombosis in moderate-risk patients and is administered without laboratory monitoring. However, in very high-risk patients such as those having hip surgery, the incidence of thrombosis is approximately 25 percent and of proximal vein thrombosis it is 10 to 15 percent, despite low-dose heparin p r o p h y l a~i s .~~-~ The results of three studies have demonstrated that the efficacy of lowdose heparin therapy is improved without compromising safety by adjusting the dose to achieve a minimal heparin in all three, adjusted low-dose heparin therapy was significantly more effective than fixed-dose heparin therapy following hip surgery. In two of the s t~d i e s ,~~.~ the APTT was prolonged slightly (APTT ratio 1.1 to 1.2), which required a mean daily dose of heparin in excess of 18,000 U, while in the other study the APTT was maintained in the upper normal range and the mean daily dose of heparin was approximately 15,000 U. The adjusted dose regimen has limitations for routine use since it requires careful monitoring and the use of a responsive APTT system. Nevertheless, these three studies illustrate the important principle that a small heparin effect by ex oivo measurement is required for optimal prophylaxis in very high-risk patients.
Details of heparin treatment for the different indications are provided in separate chapters. A rapid therapeutic heparin effect is achieved by commencing with a loading dose of 5,000 U as an intravenous bolus followed by 32,000 U/24 h by continuous A lower dose of 24,000 U/24 h might provide adequate protection immediately after thrombolytic therapy. The APTT should be performed at appn~ximately 6 h after the bolus and the heparin dose adjusted according to the result obtained. A heparin dose adjustment nomogram has been developed for a specific APTT reagent for which the therapeutic range is 1.9 to 2.7 times control (based on a heparin level of 0.2 to 0.4 Ulml). This nomogram is not applicable to all APTT systems but can be adapted to other systems by the local laboratory. In patients with acute myocardial infarction who receive thrombolytic therapy, the lytic state often induces a transient coagulation defect that can prolong the APTT for up to 24 h."' Therefore, the dose of heparin should only be adjusted upwards in the first 24 h if the APTT is below the therapeutic range. A modified nomogram in which a high initial dose is used has also been shown to be effective in patients at low clinical risk for bleeding.H2
It is also possible to achieve therapeutic heparin levels with subcutaneous injection, but the anticoagulant effect of subcutaneous heparin is delayed for approximately 1 h and peak levels occur at approximately 3 h. If the subcutaneous mute is selected, a high initial dose should be used (35,000 U/24 h in two divided doses) to overcome the poor bioavailability of moderate doses." If a rapid effect is required, the subcritaneous injection should be preceded by an intravenous bolus of5,000 U. Monitoring is performed 6 h after injection with the aim of maintaining the APTT in the therapeutic range at this time.4'
SIDE EFFECTS

Bleeding
Bleeding is a major complication of heparin. Heparin can also produce other less common but serious complications. These are listed in Table 2 . Of these, 
Osteoporosis
An association between heparin therapy and osteoporosis has been suspected for many years." With the exception of one randomized trial with only 40 patientsM (level II), the reports have been descriptive series or case reportssffi (level IV and V). In these studies, patients with osteoporosis presented with bone pain andlor radiologic findings that included rib fractures, vertebral collapse, and asymptomatic osteopenia of thoracolumbar vertebrae. In all patients, serum calcium, phosphorus, and alkaline phosphatase values were within normal limits.
Except for one report,= the daily dose of heparin was 15,000 U or more. In three s t u d i e~,~~,~~,~ the duration of treatment was five months or less, while in all other reports treatment was in excess of six months.
In the descriptive study (level IV) by Griffith and associates," which initially drew attention to a possible association, six of ten patients who received between 15,000 and 20,000 U daily for greater than six months had development of clinical osteoporosis. None of 107 patients receiving lower doses had this complication develop.
In the other randomized controlled trial, Howell and associatesM reported that 1 of 20 women allocated to receive long-term antenatal heparin prophylaxis (10,000 U twice daily) had development of clinical osteoporosis while none of the control patients had this complication develop. This study is classified as level II because the number of patients in this trial was too small to provide a reasonable chance of demonstrating a clinically important difference. Thus, the 95 percent confidence intervals on the observed incidence of 5 percent varies from 0.13 percent to 24.87 percent.
Recently, Dahlman and associatesm reported on 70 women who received heparin therapy during pregnancy and 30 control subjects who had roentgenograms of the spine and hips one week post partumm (level 111). Twenty-five of the women received heparin for established venous thromboembolism and their average daily heparin dose was 31,400 U . The remaining 45 women received prophylactic heparin because of a history of thromboembolism; 24 received a highdose regimen, average dose 17,500 U daily. Of the patients who received heparin, 12 (17 percent) had obvious osteopenia on roentgenogram compared with none in the control group. Two women who received the high-dose prophylactic regimen had development of symptomatic spinal fractures postpartum. There was a relationship between the duration of heparin therapy and osteopenia.
Ginsberg and associatesw have recently reported the results of a case-control study (level 111) that provides further evidence for an association between heparin and osteoporosis. Sixty-one women who had received heparin for greater than one month were matched with 61 control subjects for age, parity, and duration since last pregnancy. All patients underwent dual photon absorptiometry of the lumbar spine and single photon absorptiometry of the wrist to assess bone density. There was a statistically significantly greater proportion of cases than controls with abnormally low bone density. Although none of the cases suffered symptomatic fractures, the lower bone density in these patients suggests that long-term heparin therapy has the potential to produce clinical osteoporosis in a small percentage of exposed subjects.
The mechanism for heparin-associated osteoporosis is not clear. Ambrus and associatesw demonstrated that the administration of heparin for three months to female mice can lead to significant loss of body calcium. A v i~l i~~~ reviewed the possible pathophysiologic features of heparin-associated osteoporosis and the following mechanisms were suggested: (1) potentiation of parathyroid hormone (PTH) effect on osteoclast activity; (2) decreased osteoblast activity; (3) increased bone resorption due to heparin-related collagenase activity; and (4) abnormalities in vitamin D metabolism.
It has been suggested that heparin's affinity for calcium leads to decrease in ionized calcium, which results in PTH overactivity and subsequent demineralization of bone. However, the absence of clinical evidence of parathyroid hyperplasia in patients with heparin-associated osteoporosis and the fact that the administration of heparin to PTH-deficient animals can lead to bone resorption and decreased bone formation make the role of PTH in the pathogenesis of heparin-associated osteoporosis unlikely.
In summary, although level I studies assessing the relationship between heparin exposure and osteoporosis have not been performed, it is likely that longterm heparin therapy produces osteoporosis in a small percentage of exposed individuals. The limited evidence suggests that there is a dose effect. Short-term heparin therapy (14 days or less) is unlikely to be associated with clinically important osteoporosis. It is also ri~~likely that three months of treatment with moderate doses of heparin (approsimately 20,000 U/24 h) is associated with clinically important osteoporosi~.")~ The vast majority of reports of heparillassociated osteoporosis have been in patients who were treated with at least 20,000 U/d for more than six months. The true incidence of osteoporosis in patients receiving long-term heparin therapy is uiiknown, hut it is likely to be substantial. Therefore, all patients who receive high doses of heparin for more than five months should be considered to have a significant risk of osteop)rosis developing.
Thrornhxytopenia is a well-recognized complication of heparin therapy. In most cases, it is asymptomatic I>ut rarely it is associatecl with arterial thrombosis and even less commonly with bleeding.""~lU Most cases of heparin-associated thrombocytopenia have been reported in patients receiving high doses of heparin. Thrombc~ytopenia has also been reported rarely (less than 1 percent) in patients receiving lowdose heparin prophyl;~~is","~~ and even in patients receiving heparin flrishes to maintain patency of intravascrilar cat11eters.l'""" Thrombtxytopenia is more cvmmon with heparin derived from bovine lrliig than from porcine gut."'"^"" Pooled analysis of studies ill which patients were randomized to receive high doses of heparin derived from one or other source of heparin revealed on overall incidence of thron~btxytopeiiia of 15.6 percent iri the 173 patients receiving bovine heparin and 5.8 percent in the 223 patients receiving porcine heparin"'"1evel I). Thrombocytopenia usually begiris hetween 3 and 15 days after commericing heparin therapy (median, I O days),ltr2,Itn but it has been reported within hours of commencing heparin therapy in patients who have been exposed to heparin l)reviOrlsly, 1tr2.11r. 112 The platelet count usually returns to baseline levels within four days of stopping heparin therapy."" There are reports of persistent thrombocytopenia for 7 to 14 day~'~"-"%and of an elevation of platelet coui~t despite c o~~t i n i i a t i o~~ of heparin therapy,"""h but it is uncertain whether the c:arlse of thrombocytopenia in these atypical cases is heparin related.
Heparin-associated thrombocytopenia is thought to be caused by an IgG-heparin i m m~i~l e conlplex involving both the Fab and Fc portion of the Ig<; molt~cule."" In oitro studies of heparin-i~iduced platelet aggrt5ga-tion or release have shown that a nri~rlber of I,hIWFIs cross-react with heparin when tests are performed on convalescent plasma samples of patients with heparillassociated thrombocytopenia and that the Organon hepiirinoid, Lomoparin, does not cross-react."" U1ht.ther these in oitro findings ciin be translated into the safe use of Lornoparin in patients with current or past 11elxirin-associated thrombocytopenia is uncertain at present.
Heparin-asscxiated thrombt~ytopenia can be complicated by thrombotic n~anifestations ciirised by platelet-rich thrombi. ln-l" The incidence of heparin-induced arterial thrombosis has been estimated to be 0.4 percent (4 of 1,080) in patients receiving therapelltic doses of porcine gut heparin (level 111). The most common manifestations of thrombosis are lower limb arterial thrombosis, thrombotic cerel)rovascular accidents, and myt~ardial infidrction. Venous thrombosis has also been described but it is uncertain whether this is a manifestation of heparin-associated throinbocytopenia or results from heparin resistance that has been described to occur with heparin-associated thrombocytopei~ia.~~"~" In most cases of thrombosis, t h e lowest platelet count ranges from 40,000 to 60,0001(*~l(M~':U'I:" but the degree of thrombocytopenia can be very severe with counts as low as 5,0001 ml . Bleeding complications have been described in patients with heparin-associated t h r o m b t~y t o p e n i a~~ but they are less frequent and much less important than thrombotic complications. Rarely, heparin-induced thrombosis can be heralded by a fall in platelet corlnt without overt thrombtxytopenia, eg, a fall in platelet count from 350,000 to 150,000. For this reason, patients who receive heparin should have a platelet count performed daily and if the platelet count falls l)rogressively or precipitously to less thiui 100,000/ml, heparin therapy should be stopped and an alternative management strateby instituted. Ifwarfarin treatment has already beer1 started and the international normalized ratio (INK) is approaching or in the therapeutic range, warfarin therapy can Ile continued without the addition of alternative treatment. If warfarin therapy has not been started, and heparin is being used to treat verloiis thromboembolism, a caval filter can be inserted or alternative antithrombotic agents can be used. T\vo alternative antithrombotic agents have been evaluated in descriptive studies (level V). These are the snake venom, ancrod, and the Organon heparinoid, Lomoparin. A dosage regimen for ancrod (which is still experimental in the United States but can be obtained from Knoll Pharmaceutical and stored in the pharmacy for compassionate use) is shown in Table 3 .
Patients with a history of heparin-associated thrombocytopenia who require heparin treatment present a difficult problem of management. Although examples of successful reexposure to heparin have been described, this approach is potentially dangerous. There have been a number of case reports of the successful use of LMWHs, but most fractions tested exhibit immunologic cross-reactivity with heparin when tested with convalescent plasma from patients with previous heparin-associated thr~mbocytopenia.'~~ The Organon heparinoid, Lomoparin, which is composed of heparin sulfate, dermatan sulfate, and chondroitin sulfate, exhibits minimal cross-reactivity with heparin120J31,13 and has been used successfully to treat patients with heparin-associated thrombocytopenia.1*0,L3L.138140 Other LMWHs exhibit cross-reactivity and there are reports of persisting thrombocytopenia during LMWH treatment.122,141-146 Ancrod can also be used for short-term treatment, but its long-term use is limited by the development ofantibodies that render patients resistant to its effects.
An immunologic basis for heparin-induced thrombocytopenia and thrombosis has been proposed1*' and confirmed by a number of investigator^.^^^^^^^-^" More recently, patients with heparin-associated thrombocytopenia have been reported to exhibit heparin IgG immune complexes to platelet Fc receptors with resulting platelet activation.llg Heparin has been shown to bind to platelets in a specific and saturable f a~h i o n ,~~' . '~~~~~ a process that is markedly enhanced after platelet activation.15' Heparin fractions in the highest molecule weight range and with the more extensive sulfation exhibit the greatest amount of binding.
The diagnosis of suspected heparin-induced thrombocytopenia can be confirmed by laboratory tests, which, however, are rarely useful in making clinical decisions at the time a patient presents. A test based on (14C) serotonin release of washed donor platelets plus heat-treated patient serum in the presence of therapeutic (0.1 U/ml and high 100 U/ml) heparin concentrationsLrn has been shown to be both sensitive and specific. 159,1w Heparin has been reported to produce two distinct types of skin lesions: urticarial lesions and skin necrosis.
Urticaria1 lesions occur at the site of subcutaneous injection and may be caused by a contaminant of heparin. Skin necrosis may or may not be associated with thrombocytopenia. In severe forms of skin necrosis, the tissue requires debridement and skin grafting. The reaction seems to be unrelated to the source of the heparin. The histologic features of heparin-associated skin necrosis are those of a hemorrhagic infarct of the skin and subcutaneous fat with acute necrotizing angiitis affecting small dermal vessels and extending into subcutaneous fat, features that are consistent with a hypersensitivity angiitis. White and associate^"^ reported eight cases of skin necrosis associated with heparin administration. Six occurred at the site of subcutaneous injection of heparin, but in the other two, skin necrosis occurred in association with the intravenous administration of heparin.
It has been known for some time that heparin inhibits aldosterone synthesis, probably at the step where corticosterone is converted to 18-hydroxycort i c~s t e r o n e . l~~J~* This is usually of no clinical importance, but there are three case reports of heparininduced hypoaldosteronism leading to hyperkalemia and other metabolic derangements1w165 and even death.la The hyperkalemia and hypoaldosteronism reverted to normal in two of these cases when heparin therapy was d i s c~n t i n u e d~~~~~~ (and returned on rechallenge in one of these casesIm). In these cases, the heparin was administered for less than six weeks. In the third case, the patient received therapeutic doses of heparin for four years and died of the consequences of hypoaldoster~nism.~~ Thus, selective hypoaldosteronism is a rare but probably real side effect of heparin administration.
Hypersensitivity reactions are well documented but rare. The symptoms include urticaria, conjunctivitis, rhinitis, asthma, cyanosis, tachypnea, oppressive feeling, angioneurotic edema, and anaphylactic shock. In addition, patients receiving heparin occasionally have development of local urticarial-like lesions that rapidly disappear when the drug therapy is discontinued.
Heparin has been associated with priapism in a number of case report^.^^.'^^ It is uncertain whether it is the heparin or the underlying thrombotic condition that causes the priapism.
Low MOLECULAR WEIGIIT HEPARINS
The LMWHs are a new class of anticoagulants that have been developed for clinical use. These new compounds are being used in Europe and it is anticipated that they will be approved for use in North America in the next few years.
The clinical development of LMWHs was stimulated by the observation that for equivalent antithrombotic effects in experimental models, LMWHs produced less bleeding than the standard heparin (SH) from which they were derived.'68173 These observations were followed by clinical studies that demonstrated that LMWHs are effective and safe antithrombotic agents for the prevention and treatment of venous thrombosis.
LMWHs are fragments of heparin, produced by either chemical or enzymatic dep~lymerization."~ LMWHs are approximately one third of the size of heparin; like standard heparin they are heterogeneous with respect to molecular size, with a molecular weight distribution of 1,000 to 10,000 and a mean molecular weight of 4,000 to 5,000. Depolymerization 
Anticoagulant Effects of LMWHs
Like heparin, LMWHs produce their major anticoagulant effect by binding to an antithrombin ATIII, through a unique pentasaccharide s e q u e n~e ,~, "~ which is present on less than one third of LMWH molecules.
Since a minimum chain length of 18 saccharides (including the pentasaccharide sequence) is required for ternary complex formation, only the small percentage of the larger LMWH species in each preparation are able to inactivate thrombin. In contrast, all of LMWH fragments that contain the high-affinity pentasaccharide catalyze the inactivation of factor Xa. Virtually all SH molecules contain at least 18 saccharide units while only 25 percent to 50 percent of the different LMWHs contain fragments with 18 or more saccharide ~n i t s . '~~~~~~~~~~~~" Therefore, in contrast to SH that has a ratio of antifactor Xa to antifactor IIa activity of approximately 1:1, the various commercial LMWHs have antifactor Xa to anti-IIa ratios that vary between 4:l and 2:l depending on their molecular size distribution.
Phamokinetics of LMWHs
The plasma recoveries and pharmacokinetics of heparin and LMWHs differ because of differences in their relative binding properties to plasma proteins and cells. Most heparin-binding proteins do not bind to or neutralize L M W H S .~.~~.~. '~~ The absence of protein binding of L M W H S~' .~~ contributes to their excellent bioavailability at low doses179 and to their predictable anticoagulant response when administered in fixed dose^.'^ LMWH preparations also have a lower affinity than heparin for VWF,4H a property that could contribute to the observation that LMWHs produce less experimental bleeding than heparin for equivalent anticoagulant e f f e c t~. '~'~~J~~ Unlike heparin, LMWHs do not bind to endothelial cells in ~u l t u r e ,~'~'~~~'~ a property that could be responsible for their longer plasma half-life (which is approximately twofold to fourfold longer than h e p a~-i n ) . '~-'~~ LMWHs are cleared principally by the renal route and their biologic half-life is increased in patients with renal failure. 184.191.182 
Antithmbotic and Hemorrhagic Effects of LMWHs, Heparinoids, and Standard Heparin in Experimental Models in Animals
The antithrombotic effects and hemorrhagic effects of heparin have been compared with LMWHs with the Organon heparinoid, Lomoparin, and with dermatan sulfate in a variety of experimental animal models.L6R-'73~'R'~Le3-1g7 In these models of thrombosis, temporary venous stasis is produced by ligating an appropriate vein and blood coagulation is stimulated by injecting either serum, factor Xa, thrombin, or tissue f a c t~r . '~~J~~J~ When compared on a gravimetric basis, LMWHs are slightly less effective than heparin as antithrombotic agents, but they produce much less bleeding than heparin in models measuring blood loss from a standardized injury.L6a172,'HL.'e4.LeJ
These differences in the relative antithrombotic to hemorrhagic effects of these polysaccharides could be due in part to their different effects on platelet f u n c t i~n~~~l~~'~ and vascular p e r m e a b i l i t~.~
Clinical Studies
LMWHs have a number of advantages over heparin; they have a longer plasma half-life and a more predictable anticoagulant response to weight-adjusted doses than SH. These properties allow LMWHs to be administered once daily and without laboratory monitoring. The observation in experimental animals that LMWHs produce less bleeding than SH for an equivalent antithrombotic effect allows patients to be treated with higher anticoagulant doses of LMWHs than SH without compromising patient safety. This potential advantage of LMWHs has been demonstrated in one prophylactic study in which SH produces a significant increase in bleeding when its dose was increased to match the anticoagulant effect ex viuo of a LMWH,201 and in two studies comparing high doses of a LMWH with full doses of SH for the treatment of venous thrombosis, LMWHs have been evaluated and compared with heparin in randomized clinical trials for the prevention and treatment of venous t h r o r n b o e m b~l i s r n .~~~
M e n t i o n of Venous Thrombosis
The results of studies evaluating LMWHs for the prevention of venous thrombosis have been reviewed
Heparin (Hirsh et el) e1sewhere.m For general surgical patients, LMWHs administered once daily by subcutaneous injection have been shown to reduce cardiovascular mortality when compared with placebo and to be approximately 30 percent more effective than SH 5,000 U (administered by subcutaneous injection twice or three times daily) in preventing venous thrombosis without any difference in bleeding.m
When compared with a control group, LMWHs have been shown to reduce the incidence of thrombosis in patients undergoing major knee or hip surgery by about 70 percent without increasing the risk of bleeding.2052m When compared directly with other forms of prophylaxis in orthopedic patients, LMWHs are significantly more effective than heparin 5,000 U subcutaneously administered twice or three times daily;208210 significantly more effective than oral antic o a g u l a n t~;~~~ significantly more effective than de~tran2~2.2~3 significantly more effective than aspirin (B. Davidson, written communication, 1992); and significantly more effective than adjusted-dose heparin in preventing proximal vein thrombosis. 214 LMWHs a r e very effective in patients with and in other high-risk medical patients,e17 producing a relative risk reduction in venous thrombosis of between 60 percent and 90 percent. This beneficial effect occurred without an increase in clinically important bleeding. LMWHs have also been shown to be significantly more effective than SH in preventing venous thrombosis in patients with paralytic stroke and in patients with spinal cord injury. Thus, in both studies comparing LMWHs with heparin, patients randomized to receive LMWH showed a greater than 70 percent risk reduction in thrombosis, a statistically significant d i E e r e n~e .~~~~~'~
Zhatrnent of Venous Thrombosis
LMWHs administered in a fixed dose by subcutaneous injection have been compared with dose-adjusted heparin administered by continuous infusion for the treatment of venous thrombosis. The results have been reviewed elsewhere and are discussed in more detail in this supplement. Two different outcome measures have been used. In studies using change in thrombus size assessed by repeating venography at the end of the course of treatment, LMWHs were shown to be as effective or more effective than heparin. In both studies using symptomatic recurrent venous thromboembolism as the outcome measure there was a strong trend for the LMWH to be both more effective and safer than heparin. These findings raise the possibility that selected patients with venous thrombosis might be able to be treated at home, an advance that would reduce cost and improve patient convenience.
More research is required to clanfy a number of important issues that have arisen from current studies with LMWHs.
Like heparin,zN LMWHs do not cross the placental barrier;121-223 and descriptive studies suggest they might be safe and effectivew in pregnancy.
When used for the prevention of venous thrombosis, postoperative dosing is effective,m1.2M~106~211~225~226 but it is unknown whether it is as effective as preoperative administration. The long-term use of heparin can be complicated with osteoporosis. Although there is a case report of successful use of a LMWH in a patient whose treatment with SH was complicated with symptomatic o s t e o p o r~s i s ,~~ more information from appropriately designed studies will be required before it can be concluded that this rare but troublesome side effect of heparin will be avoided by using LMWHs. There is an impression that the incidence of thrombocytopenia is less with LMWHs than heparin, but to our knowledge, this has never been confirmed in a properly designed clinical study. There are reports that the administration of LMWHs can be associated with the development of thrombocytopenia both in previously unexposed individuals1" and in those with a history of heparin-induced thrombocytopenia (HIT).l4" There is also evidence that LMWH preparations cross-react with plasma from patients with recent HIT.130 In contrast to the LMWHs, the Organon heparinoid, Lomoparin, which is essentially free of contaminating heparin, has minimal cross reactivity in in oitm assays for HITLm and has been used successhlly in patients with a history of HIT.12" There have, however, been rare reports of thrombocytopenia developing in patients treated with the Organon heparinoid, Lomoparin; whether these reported associations are causal or coincidental is unclear. 
